Rice University Researchers Built Implantable Biologic Lab
A new research-stage device aims to deliver continuous medicine via engineered cells starting in 2027.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you believe new medical innovations will effectively lower your long-term healthcare costs?
Researchers at Houston-based Rice University have developed an implantable device that utilizes engineered protein producers to deliver medicines continuously. This research-stage invention seeks to simplify long-term treatment through a single procedure.
Why it matters
The technology aims to address the high cost and accessibility barriers of biologic medicines, which currently account for over half of all drug spending. By providing a continuous delivery mechanism, this device could shift how long-term therapies are administered to patients.
The device relies on engineered protein producers capable of delivering medication continuously from a single implant. While biologics currently represent 51% of drug spending despite being only 5% of prescriptions, this system seeks to reduce the burden of frequent administration.
The players
Rice University
A Houston-based research university focused on advanced biotechnology and materials science applications.
The details
The device uses engineered protein producers to synthesize and release necessary medication directly within the body. This approach is designed to function as a living pharmacy, with the potential to provide treatment for years following a single procedure. The research is currently focused on optimizing the longevity and reliability of these protein-producing cells for future clinical applications.
Timeline
October 2, 2026: Researchers announced the invention of the living pharmacy device.
2027: The implant is scheduled to enter its first clinical trial phase.
The Tech Race
This development follows the trajectory of automated drug delivery, attempting to move beyond mechanical pumps to biological self-regulation. It represents a shift from external delivery hardware toward implanted cellular systems designed for years-long, autonomous therapeutic maintenance.
The current research aims to eventually replace frequent traditional injections with a single, long-lasting procedure for patients receiving biologics. As the technology is currently in the research stage, it is not yet available for patient use or commercial pricing.
The takeaway
This technology highlights a growing effort to reduce the clinical and financial burden of biologic-heavy treatment plans by integrating medicine production directly into the patient. Watch for the 2027 clinical trial data to see if the device maintains efficacy for extended periods as projected.
What happens next
Clinical trials for the implant are slated to begin in 2027.
Further reading
For more on the latest developments in cell-based therapies, explore our coverage of Biotech.
Live Poll
Do you believe new medical innovations will effectively lower your long-term healthcare costs?
